Stockscreener 앱 받기
0.00
0.00%
0.00
Vitro Biopharma, Inc. 주식(VTRO)의 최신 뉴스
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104Important Step in RHB-204 Development for MAP-related Crohn's Disease - PR Newswire
Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan
VTRO (Vitro Biopharma) PB Ratio : 0.00 (As of Mar. 26, 2026) - GuruFocus
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 - marketscreener.com
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Reviewing Rein Therapeutics (NASDAQ:RNTX) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Financial Contrast: Imunon (NASDAQ:IMNN) vs. Vitro Diagnostics (OTCMKTS:VODG) - Defense World
What Stem Cell Clinics Do You Trust? - BioInformant
How new approach methodologies are reshaping drug discovery - McKinsey & Company
Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment - ACCESS Newswire
Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth - ACCESS Newswire
The 16th international oncolytic virotherapy conference: from in vitro to clinical studies, novel approaches in cancer therapy meeting report - Frontiers
Vitro Biopharma | CORRESP: CORRESP - Moomoo
Dealmaking Quarterly Statistics, Q4 2024 - Citeline News & Insights
Stem Cell Therapy for the Coronavirus COVID-19 Pandemic - ACCESS Newswire
Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company
Layoffs Continued Across Biopharma in 2024 - BioSpace
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Press Release Service: Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia - CRISPR Medicine News
Vitro Biopharma(VTRO) Stock Options Chain | Quotes & News - Moomoo
Top 5 In-Vitro Diagnostics [IVD] Companies - Fortune Business Insights
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell Reprogramming Technologies for Cancer - bioinformant.com
Vitro Biopharma Company Profile & Introduction - Moomoo
EDGAR Filing Documents for 0001493152-24-004779 - SEC.gov
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
SIRION Biotech - Pharmaceutical Technology
Vitro Biopharma(VTRO) Stock Price Today | Quotes & News - Moomoo
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Kirk Cousins travels to Caribbean for stem cell treatment - kare11.com
Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com
Vitro Biopharma, Inc. (VTRO) Stock Live Price, Chart & News - CoinCodex
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com
Global Stem Cells Market Research Report 2023: Implications - GlobeNewswire
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
The Next Normal – The future of biotech: AI-driven drug discovery - McKinsey & Company
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be Used in FDA-Authorized Clinical Trial - Business Wire
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care - Business Wire
GT Biopharma Poster Presentation and Mini Oral Session at - GlobeNewswire
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million. - marketscreener.com
Vitro Biopharma Names Chris Furman Chief Executive Officer - Yahoo Finance
Biotech - McKinsey & Company
Business of Biotechniques 2022 - biotechniques.com
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online
FinancialContentAytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells - FinancialContent
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19 - bioinformant.com
DVC Stem: Stem Cell Therapy Clinic in the Cayman Islands - bioinformant.com
Nutrition Startup Introduces New Category in Health that Will Change Mankind's Approach to Human Nutrition - Yahoo Finance
In vitro glycoengineeringSuitability for BioPharma manufacturing - Labroots
Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R) - BioInformant
Vor Biopharma Raises $110M to Develop Engineered Hematopoietic Stem Cells - BioInformant
Stem Cell Therapy for Coronavirus Infection - ACCESS Newswire
VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30 th 2019 financial results of operations. - SEC.gov
Vitro Biopharma Obtains CLIA Certification Complimenting its Ongoing Stem Cell Clinical Trials - ACCESS Newswire
Fujifilm Acquiring Irvine Scientific, IS Japan for $800M, with Cell Culture Media Growth in Mind - Genetic Engineering and Biotechnology News
Global Stem Cell Technologies and Applications Market 2018-2018Visiongain Report - PR Newswire UK
Human Organs-on-Chips - Wyss Institute at Harvard
Merck KGaA debuts new fertility tech division - BioPharma Dive
Vitro Diagnostics (VODG) Stock Price, News & Analysis - MarketBeat
1.27%
1.43%
자본화:
|
볼륨(24시간):